TAIPEIBIO CO., LTD.
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
1. NeoGraft
2. NeoGraft C
3. NeoGraft E
2. NeoGraft C
3. NeoGraft E
Founded Year
2014
Unified Business No.
24552024
Status
Active
Number of Employees
0
Total Paid-in
Capital
81,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taipeibio is a pioneer of regenerative-collagen driven tissue regeneration technology, and can repair various bone defects in bone, joint, ligament and cartilage. We are involved with some of the top notch medical materials in tissue regeneration. Taipeibio has decades of experience in gene regulation/ Nano DMX® (Duo Matrix) technologies and for 15 years has had convincing top stress-bearing data proving safety and efficacy. This includes more than 50 high-impact papers published and 20 patents approved in the U.S.. (IP firms: Fish & Richardson / Cesari & McKenna Boston)
In 2015, we built a GMP-compliance facility in Boston area (New England Osteogenesis Inc.. -NEO) supported by our research arms with the followings,
- successfully transferred our R&D platform and manufacturing process from our Taiwan government-funding lab to U.S. for GMP mass production in 2018.
- a comprehensive quality control of source materials and optimized manufacturing process and know-how to minimize the cost and to accelerate the process for FDA fast-track clearance.
Taipeibio founder Dr. Thomas Wen-Fu Lai has contributed to tissue engineering and molecular imaging technologies for over 30 years and is a pioneer researcher in the field of tissue regeneration (SG/MG Lab-Harvard, IY Lab-MIT 1989) and bone/cartilage molecular imaging (RW Lab-MGH 2000).
In 2015, we built a GMP-compliance facility in Boston area (New England Osteogenesis Inc.. -NEO) supported by our research arms with the followings,
- successfully transferred our R&D platform and manufacturing process from our Taiwan government-funding lab to U.S. for GMP mass production in 2018.
- a comprehensive quality control of source materials and optimized manufacturing process and know-how to minimize the cost and to accelerate the process for FDA fast-track clearance.
Taipeibio founder Dr. Thomas Wen-Fu Lai has contributed to tissue engineering and molecular imaging technologies for over 30 years and is a pioneer researcher in the field of tissue regeneration (SG/MG Lab-Harvard, IY Lab-MIT 1989) and bone/cartilage molecular imaging (RW Lab-MGH 2000).
